Medicenna Gets FDA Go-Ahead To Proceed With Phase 3 Study Of MDNA55 In Recurrent Glioblastoma

Medicenna Therapeutics Corp. (MDNA) (MDNA.TO) has been advised to proceed with a hybrid phase III registration trial of MDNA55 in recurrent glioblastoma, following a recent End of phase II meeting with the FDA.

from RTT - Biotech https://ift.tt/34ZBnLo
via IFTTT